Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
about
Role of Oxidative Stress in Drug-Induced Kidney InjurySafe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency AnemiaA randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.Increased renal iron accumulation in hypertensive nephropathy of salt-loaded hypertensive ratsRandomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study.How to limit allogenic blood transfusion in children.Haemodialysis-associated anaphylactic and anaphylactoid reactions.Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease.Use of ibandronate in the prevention of skeletal events in metastatic breast cancer.International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.Prolonged recovery time from zoledronic Acid induced acute tubular necrosis: a case report and review of the literature.Iron deficiency in the elderly population, revisited in the hepcidin era.Iron deficiency anemia in heart failure.Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.Renal transplantation in autosomal dominant polycystic kidney disease.Hypersensitivity to intravenous iron: classification, terminology, mechanisms and managementAn uncommon infection in an uncommon host.High-dose iron gluconate in chronic kidney disease patients.Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up.Update on adverse drug events associated with parenteral iron.Lanthanum carbonate.Bisphophonates in CKD patients with low bone mineral density.The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: a light and electron microscopy study.Therapeutic use of the phosphate binder lanthanum carbonate
P2860
Q28074502-73B880ED-849D-4311-9F62-003B27BEA627Q33279821-7AB01BF1-55D3-49E5-A05B-5CCA612D7976Q33583025-E9310352-D186-47E8-9896-474062E37488Q33607976-446B4471-7E72-44B7-9105-24FFB4E92A08Q34885195-A872D74D-E8DC-4541-90E7-9D0CC6C30974Q35014571-8AFABC58-5832-436D-BF6A-7FFE54BE7303Q35955686-97801FCE-9BD2-4A17-8559-43C0C8832736Q36292194-6DDA41BC-6871-495C-962A-B8A794D96090Q36366935-0DEC67AF-3844-45CF-A3DF-4E7A4880D3C9Q36636085-B3B3A331-E47F-4BB4-A7E5-B09E170DB6DDQ36823566-8427D54C-7D35-472B-9539-C71C3366AD90Q36929923-A8E43797-10FD-46F2-A916-B2E26B7E0A6FQ37556076-466B5E07-E5FD-4D9D-AF21-BEF626F0E91BQ37734983-14E2291D-ABAF-41E7-B8B4-283F9F476C98Q38040656-C3A12832-13E5-4469-92F2-21297AE1BDDEQ38213232-4C08C840-E5A3-4200-87F4-BD6D0A362D94Q38220783-B4B43E80-27C4-4F62-B3D9-A119A2EFA70CQ38564991-B81E4E49-0E96-4F21-98CD-3BF9C481ABB6Q40336223-2BF353E7-B7CB-4A85-8891-04F425C722BDQ44783615-B6BC1A60-81B6-467B-A4C6-7E38D0BF14BBQ46062433-3D05407D-51FC-4B77-A58B-571A99AA0A1DQ46212164-2A1BDD1F-90CD-40B5-AA15-4ECE7BE5CACDQ46921582-7B221BDC-92B5-4CB6-B52C-8514AB782A0DQ54313739-3F9530A7-0F05-4C21-899C-E6CB88E6EC52Q55343608-30D95CD6-6B01-4AE0-808E-1B740A62D93FQ57220755-2F3F807A-5ABE-44E7-B7C6-EE9E489162F1
P2860
Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@ast
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@en
type
label
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@ast
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@en
prefLabel
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@ast
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@en
P2093
P1476
Short-term, high-dose pamidron ...... bisphosphonate nephrotoxicity.
@en
P2093
David Roth
Debasish Banerjee
Jacques J Bourgoignie
Liliane Striker
Richard A Preston
P356
10.1016/S0272-6386(03)00373-1
P577
2003-05-01T00:00:00Z